In its annual report issued on April 26, 2024, Drugmaker disclosed ongoing connected transactions related to the licensing and strategic alliance agreement entered into with Juno Therapeutics, Inc. (“Juno”), one of its major shareholders. The agreement, effective December 13, 2017, grants the right to develop and commercialize Juno's T cell engineering products and technologies in specific areas. Juno is subject to prepayment, milestone payments, license fees and compensation to Juno. Under the Listing Rules, the transaction is considered a continuing connected transaction and is exempt from 21 July 2022 until 31 August 2024. Pharmacyclo applied for a further extension of the exemption on 2 April 2024, with reasons including the commercialization progress of Relma-cel and the expected approval of the new drug application. On April 22, 2024, the exchange approved the extension of the exemption until December 31, 2026 and set the conditions. The Board considers the transaction under the Licensing and Strategic Alliance Agreement to be fair and reasonable and in the best interests of the Company and its shareholders.

In its annual report issued on April 26, 2024, Drugmaker disclosed ongoing connected transactions related to the licensing and strategic alliance agreement entered into with Juno Therapeutics, Inc. (“Juno”), one of its major shareholders. The agreement, effective December 13, 2017, grants the right to develop and commercialize Juno's T cell engineering products and technologies in specific areas. Juno is subject to prepayment, milestone payments, license fees and compensation to Juno. Under the Listing Rules, the transaction is considered a continuing connected transaction and is exempt from 21 July 2022 until 31 August 2024. Pharmacyclo applied for a further extension of the exemption on 2 April 2024, with reasons including the commercialization progress of Relma-cel and the expected approval of the new drug application. On April 22, 2024, the exchange approved the extension of the exemption until December 31, 2026 and set the conditions. The Board considers the transaction under the Licensing and Strategic Alliance Agreement to be fair and reasonable and in the best interests of the Company and its shareholders.